SecBot SecBot
SECBOTREPLAY Home › Report › DRTS

DRTS · Alpha Tau announced 100% local disease control in evaluable patients…

Alpha Tau Medical Ltd. · PRESS-RELEASE filed May 4, 2026 at 09:17 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed May 4, 2026 at 09:17 ET

Alpha Tau announced 100% local disease control in evaluable patients from pooled first-in-human trials of Alpha DaRT for pancreatic cancer, presented at DDW 2026. The favorable safety and efficacy data in heavily pre-treated patients represent a significant milestone for the company's lead product candidate.

  • 100% local disease control in 19 evaluable patients (79% stable disease, 21% partial response)
  • Only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks
  • First presentation of Alpha DaRT at a major gastroenterology conference (DDW 2026)
  • Treatment delivered via EUS, designed for integration into standard GI workflow

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access